|
1) Passamonti F, Brusamolino E, Bernasconi C, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica. 2000; 85: 1011-8
|
|
|
|
2) Marchioli R, Finazzi G, Barbui T, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005; 23: 2224-32
|
|
|
|
|
3) Gangat N, Strand J, Tefferi A, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007; 138: 354-8
|
|
|
|
|
|
4) Chim CS, Kwong YL, Liang R, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005; 165: 2651-8
|
|
|
|
|
|
5) Jensen MK, de Nully Brown P, Hasselbalch HC, et al. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000; 65: 132-9
|
|
|
|
|
|
6) Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005; 366: 1945-53
|
|
|
|
|
|
7) Carobbio A, Finazzi G, Barbui T, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007; 109: 2310-3
|
|
|
|
|
|
8) De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008; 93: 372-80
|
|
|
|
|
|
9) Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008; 22: 2020-8
|
|
|
|
|
|
10) Chait Y, Condat B, Brière JB, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005; 129: 553-60
|
|
|
|
|
|
11) Brière JB. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost. 2006; 32: 208-18
|
|
|
|
|
|
12) Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006; 107: 4214-22
|
|
|
|
|
|
13) Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science. 1980; 207: 541-3
|
|
|
|
|
|
14) Wautier MP, El Nemer W, Wautier JL, et al. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha 5 chain and Lu/BCAM. Blood. 2007; 110: 894-901
|
|
|
|
|
|
15) Michiels JJ, Berneman Z, Schroyens W, et al. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost. 2006; 32: 174-207
|
|
|
|
|
|
16) Cortelazzo S, Finazzi G, Barbui T, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995; 332: 1132-6
|
|
|
|
|
|
17) Colaizzo D, Amitrano L, Margaglione M, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007; 5: 55-61
|
|
|
|
|
|
18) Boissinot M, Lippert E, Hermouet S, et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood. 2006; 108: 3223-4
|
|
|
|
|
|
19) Primignani M, Barosi G, Mannucci PM, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006; 44: 1528-34
|
|
|
|
|
|
20) Patel RK, Lea NC, Mufti GJ, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006; 130: 2031-8
|
|
|
|
|
|
21) De Stefano V, Fiorini A, Leone G, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007; 5: 708-14
|
|
|
|
|
|
22) Kiladjian JJ, Cervantes F, Valla DC, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008; 111: 4922-9
|
|
|
|
|
|
23) Pardanani A, Lasho TL, Tefferi A, et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc. 2008; 83: 457-9
|
|
|
|
|
|
24) Arellano-Rodrigo E, Alvarez-Larrán A, Cervantes F, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006; 91: 169-75
|
|
|
|
|
|
25) Falanga A, Marchetti M, Barbui T, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol. 2007; 35: 702-11
|
|
|
|
|
|
26) Carobbio A, Finazzi G, Barbui T, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008; 112: 3135-7
|
|
|
|
|
|
27) Marchetti M, Castoldi E, Falanga A, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008; 112: 4061-8
|
|
|
|
|
|
28) Sozer S, Fiel MI, Hoffman R, et al. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009; 113: 5246-9
|
|
|
|
|
|
29) Santilli F, Romano M, Davì G. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood. 2008; 112: 1085-90
|
|
|
|
|
|
30) Harrison CN, Campbell PJ, Green AR, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353: 33-45
|
|
|
|
|
|
31) Maugeri N, Giordano G, Donati MB, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug？ J Thromb Haemost. 2006; 4: 2593-8
|
|
|
|
|
|
32) Landolfi R, Marchioli R, Barbui T, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004; 350: 114-24
|
|
|
|
|
|
33) Ruggeri M, Rodeghiero F, Barbui T, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood. 2008; 111: 666-71
|
|
|
|
|